Get the Stockscreener App
14.44
0.23%
0.065
Fulgent Genetics Inc stock is traded at $14.44, with a volume of 254.30K.
It is up +0.23% in the last 24 hours and down -37.30% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$14.37
Open:
$14.15
24h Volume:
254.30K
Relative Volume:
0.75
Market Cap:
$450.66M
Revenue:
$322.67M
Net Income/Loss:
$-61.63M
P/E Ratio:
-7.3446
EPS:
-1.9654
Net Cash Flow:
$-124.21M
1W Performance:
+1.08%
1M Performance:
-37.30%
6M Performance:
-34.17%
1Y Performance:
-17.60%
1-Day Range:
$14.15
$14.72
1-Week Range:
$14.00
$15.26
52-Week Range:
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
14.43 | 448.78M | 322.67M | -61.63M | -124.21M | -1.9654 |
|
TMO
Thermo Fisher Scientific Inc
|
476.98 | 184.15B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
189.24 | 137.93B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
580.13 | 47.82B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
112.15 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
289.14 | 29.19B | 3.17B | 642.63M | 516.49M | 10.77 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha
Fulgent Genetics (FLGT) Earnings Transcript - AOL.com
Aug Sectors: Should I hold or sell Fulgent Genetics Inc now2026 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
Fulgent Genetics Hits New 52-Week Low at $14.01 Amid Declining Performance - Markets Mojo
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Technical Analysis: Is Fulgent Genetics Inc a top pick in the sectorQuarterly Earnings Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - PR Newswire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - FinancialContent
FLGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CFO has shares withheld for RSU taxes - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CEO has shares withheld for taxes - Stock Titan
Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused ExpansionWhat's Changed - Yahoo Finance
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
UBS Adjusts Fulgent Genetics Price Target to $22 From $35, Maintains Buy Rating - marketscreener.com
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results - marketscreener.com
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress - simplywall.st
A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Fulgent Genetics (NASDAQ:FLGT) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Fulgent Q4 2025 slides: EPS beats, but customer loss drives stock plunge - Investing.com Australia
Fulgent Genetics (FLGT) Loss Widening In Q4 2025 Tests Bullish Growth Narratives - simplywall.st
Fulgent Genetics (FLGT) Reports Strong Q4 Revenue Growth - GuruFocus
Fulgent Genetics (NASDAQ:FLGT) Issues FY 2026 Earnings Guidance - MarketBeat
Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Na - GuruFocus
Fulgent Genetics Q4 Earnings Call Highlights - MarketBeat
Fulgent Genetics (FLGT) Reports Strong Q4 Earnings Despite Reven - GuruFocus
Earnings call transcript: Fulgent Genetics Q4 2025 beats EPS estimates, stock tumbles - Investing.com
Fulgent Genetics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fulgent Genetics earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada
Fulgent Genetics, Inc. (FLGT) Q4 Earnings Top Estimates - Yahoo Finance
Fulgent Genetics Posts 2025 Results and 2026 Outlook - TipRanks
Fulgent Genetics (FLGT) Reports Q4 Revenue Below Expectations - GuruFocus
FLGT Projects FY26 Revenue and Financial Outlook - GuruFocus
Fulgent Genetics Q4 Non-GAAP Net Income, Revenue Rise; 2026 Guidance Set -- Shares Down Pre-Bell - marketscreener.com
(FLGT) Fulgent Genetics Expects 2026 Revenue About $350M, vs. FactSet Est of $356.3M - marketscreener.com
(FLGT) Fulgent Expects 2026 Adjusted Loss About $1.45 a Share, vs. FactSet Est of $0.32 Loss - marketscreener.com
FULGENT GENETICS ($FLGT) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (FLGT) Fulgent Genetics Posts Q4 Revenue $83.3M, vs. FactSet Est of $85.4M - marketscreener.com
Earnings Flash (FLGT) Fulgent Genetics Posts Q4 Adjusted EPS $0.16, vs. FactSet Est of $0.03 - marketscreener.com
Fulgent Genetics, Inc. SEC 10-K Report - TradingView
Fulgent Genetics Q4 revenue misses; forecasts about $350 mln in 2026 revenue - TradingView
Fulgent Genetics Q4 Earnings Assessment - Benzinga
BRIEF-Fulgent Genetics Q4 Revenue USD 83.336 Million - TradingView
Earnings Preview: Fulgent Genetics - Benzinga
Fulgent Genetics (FLGT) CEO receives stock awards and tax share withholding - Stock Titan
Fulgent Genetics (FLGT) COO receives stock awards and tax withholdings - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CFO gets equity awards, covers taxes - Stock Titan
ETF Watch: How liquid is Fulgent Genetics Inc stockQuarterly Market Review & Technical Entry and Exit Alerts - baoquankhu1.vn
Price-Driven Insight from (FLGT) for Rule-Based Strategy - Stock Traders Daily
Aug Wrap: Is Fulgent Genetics Inc a top pick in the sectorJuly 2025 Sentiment & Technical Pattern Based Buy Signals - baoquankhu1.vn
Highs Report: Will DALN benefit from rate cutsQuarterly Risk Review & Stepwise Trade Execution Plans - baoquankhu1.vn
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):